1. Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission
- Author
-
Marina Díaz-Beyá, Harry C. Schouten, Mauricette Michallet, Mohamad Mohty, Jordi Esteve, Jorge Sierra, Arnon Nagler, Gérard Socié, Myriam Labopin, Mahmoud Alijurf, Jakob Passweg, Nicolaas Schaap, Rainer Schwerdtfeger, Beelen Dietrich, Emmanuelle Polge, Johan Maertens, Liisa Volin, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: MA Hematologie (9), and Interne Geneeskunde
- Subjects
Oncology ,Male ,Disease status ,PROGNOSIS ,BLOOD ,Oncogene Proteins, Fusion ,Chromosomal Proteins, Non-Histone ,Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2] ,Medizin ,Graft vs Host Disease ,Internal tandem duplication ,Kaplan-Meier Estimate ,Translocation, Genetic ,0302 clinical medicine ,hemic and lymphatic diseases ,Gene Duplication ,Medicine ,Poly-ADP-Ribose Binding Proteins ,Oncogene Proteins ,Marrow transplantation ,Incidence (epidemiology) ,Remission Induction ,Hematology ,Middle Aged ,Allografts ,EUROPEAN-SOCIETY ,3. Good health ,Leukemia, Myeloid, Acute ,surgical procedures, operative ,Treatment Outcome ,aml ,030220 oncology & carcinogenesis ,Chromosomes, Human, Pair 6 ,Female ,Cord Blood Stem Cell Transplantation ,Stem cell ,Chromosomes, Human, Pair 9 ,Adult ,medicine.medical_specialty ,internal tandem duplication ,dek-nup214 ,ACUTE MYELOID-LEUKEMIA ,Disease-Free Survival ,CLASSIFICATION ,allo-SCT ,working party ,03 medical and health sciences ,9) aml ,Internal medicine ,Humans ,In patient ,Proportional Hazards Models ,Peripheral Blood Stem Cell Transplantation ,business.industry ,Complete remission ,Transplantation ,Nuclear Pore Complex Proteins ,fms-Like Tyrosine Kinase 3 ,business ,t(6 ,030215 immunology - Abstract
Contains fulltext : 220562.pdf (Publisher’s version ) (Closed access) Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is a poor-risk entity, commonly associated with FLT3-ITD (internal tandem duplication). Allogeneic stem-cell tranplantation (allo-SCT) is recommended, although studies analysing the outcome of allo-SCT in this setting are lacking. We selected 195 patients with t(6;9) AML, who received a first allo-SCT between 2000 and 2016 from the EBMT (European Society for Blood and Marrow Transplantation) registry. Disease status at time of allo-SCT was the strongest independent prognostic factor, with a two-year leukaemia-free survival and relapse incidence of 57% and 19% in patients in CR1 (first complete remission), 34% and 33% in CR2 (second complete remission), and 24% and 49% in patients not in remission, respectively (P < 0.001). This study, which represents the largest one available in t(6;9) AML, supports the recommendation to submit these patients to allo-SCT in CR1.
- Published
- 2020
- Full Text
- View/download PDF